Law360, New York (November 01, 2012, 12:48 PM ET) -- In In re Droge, the federal circuit upheld the decision of the U.S. Patent and Trademark Office Board of Patent Appeals and Interferences that found that claims directed to recombinant biotechnology methods were obvious. At eight pages, the decision is one of the shortest precedential opinions that I’ve read, and illustrates the difficulty of overturning a board decision of obviousness.
The Patent Application at Issue
The patent application at issue was published as US 2003/0027337. Claim 29 was deemed to be representative, and is set forth...
Reversing USPTO Appellate Board Ruling: Not An Easy Task
To view the full article, take a free trial now.
